Addex Therapeutics Ltd ADXN
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | 28.57% | -49.74% | |||
| Total Revenue | 28.57% | -50.51% | |||
| Cost of Revenue | 4.34% | -30.26% | |||
| Gross Profit | 2.20% | 21.60% | |||
| SG&A Expenses | 35.67% | -38.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.34% | -37.50% | |||
| Operating Income | -33.42% | 37.24% | |||
| Income Before Tax | -1.12% | 4.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.12% | 4.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.12% | 5.03% | |||
| EBIT | -33.42% | 37.24% | |||
| EBITDA | -33.45% | 37.25% | |||
| EPS Basic | 2.17% | 5.64% | |||
| Normalized Basic EPS | 1.74% | 5.74% | |||
| EPS Diluted | 2.17% | 5.64% | |||
| Normalized Diluted EPS | 1.74% | 5.74% | |||
| Average Basic Shares Outstanding | 3.43% | 0.55% | |||
| Average Diluted Shares Outstanding | 3.43% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||